Glatiramer Acetate - Drugs
- ️Keating, Gillian M.
- ️Wed Sep 19 2012
Behan PO, Chaudhuri A, Roep BO. The pathogenesis of multiple sclerosis revisited. J R Coll Physicians Edinb 2002; 32: 244–65
World Health Organization. Neurological disorders: a public health approach [online]. Available from URL: http://www.who.int/mental_health/neurology/chapter_3_a_neuro_disorders_public_h_challenges.pdf [Accessed 2010 Jan 26]
Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010 Mar; 9(5): A387–94
Ryan M, Deno S, Zwibel HL. Review of the clinical debate regarding interventions for multiple sclerosis. J Manag Care Pharm 2009; 15 (Suppl. S-b): S1–17
Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009 Oct 31; 374(9700): 1503–11
Tintoré M. New options for early treatment of multiple sclerosis. J Neurol Sci 2009 Feb 1; 277 Suppl. 1: S9–11
Miller JR. The importance of early diagnosis of multiple sclerosis. J Manage Care Pharm 2004 Jun; 10 (3 Suppl. 2): S4–11
Chaudhuri A, Behan PO. Treatment of multiple sclerosis: beyond the NICE guidelines. QJM 2005 May; 98(5): 373–8
Teva Pharmaceutical Ltd. Copaxone — the leading multiple sclerosis therapy [online]. Available from URL: http://www.tevapharm.com/copaxone/ [Accessed 2010 May 26]
Teva Pharmaceuticals Ltd. Copaxone® (glatiramer acetate) solution for subcutaneous injection: US prescribing information highlights [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020622s057lbl.pdf [Accessed 2009 Nov 23]
Teva Pharmaceuticals Ltd. Copaxone® 20 mg/mL, solution for injection, pre-filled syringe: UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk/medicine/17516/SPC/Copaxone+20mg+ml%2c+Solution+For+Injection%2c+Pre-Filled+Syringe/ [Accessed 2009 Nov 23]
Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurother 2007 Oct; 4(4): 647–53
Blanchette F, Neuhaus O. Glatiramer acetate: evidence for a dual mechanism of action. J Neurol 2008 Mar; 255 Suppl. 1: 26–36
Simpson D, Noble S, Perry C. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis. CNS Drugs 2002; 16(12): 825–50
Arnon R, Aharoni R. Neurogenesis and neuroprotection in the CNS: fundamental elements in the effect of glatiramer acetate on treatment of autoimmune neurological disorders. Mol Neurobiol 2007; 36 245–53
Blanchette F. Clinical significance of glatiramer acetate antibodies. Mult Scler 2007 May; 13 Suppl. 1: S28–35
Farina C, Weber MS, Meinl E, et al. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol 2005 Sep; 4(9): 567–75
Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci USA 2000 Jun 20; 97(13): 7452–7
Chen M, Gran B, Costello K, et al. Glatiramer acetate induces a Th2-biased response and crossreactivity with myelin basic protein in patients with MS. Mult Scler 2001 Aug; 7(4): 209–19
Chen M, Conway K, Johnson KP, et al. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci 2002 Sep 15; 201(1-2): 71–7
Duda PW, Schmied MC, Cook SL, et al. Glatiramer acetate (Copaxone®) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest 2000 Apr; 105(7): 967–76
Valenzuela RM, Kaufman MD, Russo PC, et al. Predictive biomarkers of clinical responses to glatiramer acetate therapy in multiple sclerosis [abstract no. P09.097]. Neurology 2009 Mar 17; 72 Suppl. 3: A469
Valenzuela RM, Rus H, Ito K, et al. Modulation of IL-18 and caspase-1 expression correlates with the clinical response to glatiramer acetate in multiple sclerosis [abstract no. P03.180]. Neurology 2006 Mar 14; 66 Suppl. 2: A75
Miller A, Shapiro S, Gershtein R, et al. Treatment of multiple sclerosis with copolymer-1 (Copaxone®): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol 1998 Dec; 92 (1-2): 113–21
Sellebjerg F, Krakauer M, Hesse D, et al. T cell activation and Th2 cytokine secretion correlate with disease activity in multiple sclerosis patients treated with glatiramer acetate [abstract no. P09.104]. Neurology 2009 Mar 17; 72 Suppl. 3: A471
Hestvik ALK, Skorstad G, Price DA, et al. Multiple sclerosis: glatiramer acetate induces anti-inflammatory T cells in the cerebrospinal fluid. Mult Scler 2008 Jul; 14(6): 749–58
Valenzuela RM, Balashov K, Ito K, et al. Time course and functional capacity of glatiramer acetate-induced regulatory T-cells in multiple sclerosis patients [abstract no. P233]. 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and the 12th Annual Conference of Rehabilitation in MS; 2007 Oct 11–14; Prague
Chiarini M, Sottini A, Ghidini C, et al. Renewal of the T-cell compartment in multiple sclerosis patients treated with glatiramer acetate. Mult Scler 2010 Feb; 16(2): 218–27
Burger D, Molnarfi N, Weber MS, et al. Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis. Proc Natl Acad Sci U S A 2009 Mar 17; 106(11): 4355–9
Li Q, Milo R, Panitch H, et al. Glatiramer acetate blocks the activation of THP-1 cells by interferon-g. Eur J Pharmacol 1998; 342: 303–10
Kim HJ, Ifergan I, Antel JP, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol 2004 Jun 1; 172(11): 7144–53
Weber MS, Starck M, Wagenpfeil S, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 2004 Jun; 127 Pt 6: 1370–8
Vieira PL, Heystek HC, Wormmeester J, et al. Glatiramer acetate (copolymer-1, Copaxone®) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J Immunol 2003 May 1; 170(9): 4483–8
Sanna A, Fois ML, Arru G, et al. Glatiramer acetate reduces lymphocyte proliferation and enhances IL-5 and IL-13 production through modulation of monocyte-derived dendritic cells in multiple sclerosis. Clin Exp Immunol 2006 Feb; 143(2): 357–62
Jung S, Siglienti I, Grauer O, et al. Induction of IL-10 in rat peritoneal macrophages and dendritic cells by glatiramer acetate. J Neuroimmunol 2004 Mar; 148(1-2): 63–73
Hussien Y, Sanna A, Söderström M, et al. Glatiramer acetate and IFN-b act on dendritic cells in multiple sclerosis. J Neuroimmunol 2001 Dec; 121(1-2): 102–10
Stasiolek M, Bayas A, Kruse N, et al. Impaired maturation and altered regulatory function of plasmacytoid dendritic cells in multiple sclerosis. Brain 2006 May; 129(5): 1293–305
Chabot S, Yong FP, Le DM, et al. Cytokine production in T lymphocyte-microglia interaction is attenuated by glatiramer acetate: a mechanism for therapeutic efficacy in multiple sclerosis. Mult Scler 2002 Aug; 8(4): 299–306
Valenzuela RM, Sicsic C, Brenner T, et al. Correlation of glatiramer acetate (GA) antibodies and cytokine shifts with clinical response to GA in multiple sclerosis [abstract no. P01.053]. Neurology 2007 Mar 20; 68 Suppl. 1: A20
Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008 Oct; 7(10): 903–14
Aharoni R, Kayhan B, Eilam R, et al. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc Natl Acad Sci U S A 2003 Nov 25; 100(24): 14157–62
Aharoni R, Eilam R, Domev H. The immunomodulator glatiramer acetate augments the expression of neurotrophic factors in brains of experimental autoimmune encephalomyelitis mice. Proc Natl Acad Sci U S A 2005 Dec 27; 102(52): 19045–50
Aharoni R, Aizman E, Fuchs O, et al. Transplanted myogenic progenitor cells express neuronal markers in the CNS and ameliorate disease in experimental autoimmune encepha-lomyelitis. J Neuroimmunol 2009 Oct; 215(1-2): 73–83
Sarchielli P, Zaffaroni M, Floridi A, et al. Production of brain-derived neurotrophic factor by mononuclear cells of patients with multiple sclerosis treated with glatiramer acetate, interferon-b 1a, and high doses of immuno-globulins. Mult Scler 2007 Apr; 13(3): 313–31
Blanco Y, Moral EA, Costa M, et al. Effect of glatiramer acetate (Copaxone®) on the immunophenotypic and cytokine profile and BDNF production in multiple sclerosis: a longitudinal study. Neurosci Lett 2006 Oct 6; 406(3): 270–5
Azoulay D, Vachapova V, Shihman B, et al. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol 2005 Oct; 167(1-2): 215–8
Gilgun-Sherki Y, Panet H, Holdengreber V, et al. Axonal damage is reduced following glatiramer acetate treatment in C57/bl mice with chronic-induced experimental autoimmune encephalomyelitis. Neurosci Res 2003 Oct; 47(2): 201–7
Aharoni R, Arnon R, Eilam R. Neurogenesis and neuroprotection induced by peripheral immunomodulatory treatment of experimental autoimmune encephalomyelitis. J Neurosci 2005 Sep 7; 25(36): 8217–28
Aharoni R, Herschkovitz A, Eilam R, et al. Demyelination arrest and remyelination induced by glatiramer acetate treatment of experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 2008 Aug 12; 105(32): 11358–63
Maier K, Kuhnert AV, Taheri N, et al. Effects of glatiramer acetate and interferon-b on neurodegeneration in a model of multiple sclerosis: a comparative study. Am J Pathol 2006 Oct; 169(4): 1353–64
Skihar V, Silva C, Chojnacki A, et al. Promoting oligo-dendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate. Proc Natl Acad Sci U S A 2009 Oct 20; 106(42): 17992–7
Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”. Neurology 2001 Aug 28; 57(4): 731–3
Arnold DL, Narayanan S, Antel S. Treatment with glatiramer acetate protects axons in patients with clinically isolated syndromes: evidence from the PreCISe trial [abstract no. 17]. Mult Scler 2008 Sep; 14 Suppl. 1: S10
Khan O, Shen Y, Caon C, et al. Axonal metabolic recovery and potential neuroprotective effect of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2005 Dec; 11(6): 646–51
Khan O, Shen Y, Bao F, et al. Long-term study of brain 1H-MRS study in multiple sclerosis: effect of glatiramer acetate therapy on axonal metabolic function and feasibility of long-term 1H-MRS monitoring in multiple sclerosis. J Neuroimaging 2008; 18: 314–9
Perumal JS, Hreha S, Shen Y, et al. Six-year prospective multi-voxel brain MRS study of two cohorts in RRMS to examine the effect of glatiramer acetate on neuronal/axonal metabolic injury [abstract no. P03.083]. Neurology 2009 Mar 17; 72 Suppl. 3: A143
Rieckmann P, Kallmann BA, Maeurer M, et al. The Val66Met BDNF polymorphism in multiple sclerosis: potential biomarker for treatment response to glatiramer acetate [abstract no. P07.126]. Neurology 2008 Mar 11; 70 Suppl. 1: A374
Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multi-center, double-blind, placebo-controlled trial. Neurology 1995 Jul 1; 45(7): 1268–76
Ure DR, Rodriguez M. Polyreactive antibodies to glatiramer acetate promote myelin repair in murine model of demyelinating disease. FASEB J 2002 Aug; 16(10): 1260–2
Brenner T, Arnon R, Sela M, et al. Humoral and cellular immune responses to copolymer 1 in multiple sclerosis patients treated with Copaxone®. J Neuroimmunol 2001 Apr; 115(1-2): 152–60
Karussis D, Teitelbaum D, Sicsic C, et al. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol 2010 Mar 30; 220(1-2): 125–30
Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol 2001 Mar; 49(3): 290–7
Achiron A, Feldman A, Gurevich M. Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. Dis Markers 2009; 27: 63–73
Lobel E, Riven-Kreitman R, Amselem A, et al. Copolymer-1. Drugs Future 1996 Feb; 21(2): 131–4
Neuhaus O, Kieseier BC, Hartung H-P. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis. J Neurol Sci 2007 Aug 15; 259(1-2): 27–37
Ziemssen T, Neuhaus O, Hohlfeld R. Risk-benefit assessment of glatiramer acetate in multiple sclerosis. Drug Saf 2001; 24(13): 979–90
Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review: glatiramer acetate [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/020622_S015_COPAXONE_INJECTION_AP.pdf [Accessed 2010 Mar 29]
O’Connor P, Filippi M, Arnason B, et al. 250 mg or 500 mg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009 Oct; 8(10): 889–97
Cadavid D, Wolansky LJ, Skurnick J, et al. Efficacy of treatment of MS with IFNbeta-1b or glatiramer acetate by monthly brain MRI in the BECOME study. Neurology 2009 Jun 9; 72(23): 1976–83. Plus supplementary material available from http://www.neurology.org [Accessed 2010 Feb 19]
Jongen PJH, Carton H, Sanders EACM, et al. FOCUS study: fatigue and quality of life in relapsing-remitting multiple sclerosis patients using glatiramer acetate improved at 6 and 12 months of treatment [abstract no. P234]. 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis and the 12th Annual Conference of Rehabilitation in MS; 2007 Oct 11–14; Prague
Ziemssen T, Hoffman J, Apfel R, et al. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes 2008; 6: 67
Zwibel HL. Glatiramer acetate in treatment-naive and prior interferon-b-1b-treated multiple sclerosis patients. Acta Neurol Scand 2006 Jun; 113(6): 378–86
Miller A, Spada V, Beerkircher D, et al. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2008 May; 14(4): 494–9
Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone®) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology 2000 Feb 22; 54(4): 813–7
Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone®) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998 Mar 1; 50(3): 701–8
Johnson KP, Brooks BR, Ford CC, et al. Glatiramer acetate (Copaxone®): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult Scler 2003 Dec; 9(6): 585–91
Johnson KP, Ford CC, Lisak RP, et al. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data. Acta Neurol Scand 2005 Jan; 111(1): 42–7
Ford CC, Johnson KP, Lisak RP, et al. A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler 2006 Jun; 12(3): 309–20
Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010 Mar; 16(3): 342–50
Schwid SR, Goodman AD, Weinstein A, et al. Cognitive function in relapsing multiple sclerosis: minimal changes in a 10-year clinical trial. J Neurol Sci 2007 Apr 15; 255(1-2): 57–63
Goodin DS, Frohman EM, Garmany GP, et al. Disease modifying therapies in multiple sclerosis: subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 2002 Jan 22; 58(2): 169–78
Wolinsky JS, Comi G, Filippi M, et al. Copaxones®’s effect on MRI-monitored disease in relasping MS is reproducible and sustained. Neurology 2002 Oct 22; 59(8): 1284–6
Rovaris M, Comi G, Rocca MA, et al. Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain 2001 Sep; 124(9): 1803–12
Cadavid D, Cheriyan J, Skurnick J, et al. New acute and chronic black holes in multiple sclerosis patients randomized to interferon beta-1b or glatiramer acetate. J Neurol Neurosurg Psychiatry 2009; 80: 1337–43
Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manage Care Pharm 2007 Apr; 13(3): 245–61
Tappenden P, McCabe C, Chilcott J, et al. Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the Medicare population. Value Health 2009 Jul 31; 12(5): 657–65
Tappenden P, Chilcott JB, Eggington S, et al. Methods for expected value of information analysis in complex health economic models: developments on the health economics of interferon-b and glatiramer acetate for multiple sclerosis. Health Technol Assess 2004 Jun; 8(27): 1–78
Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 Nov 1; 33(11): 1444–52
Pardo G, Boutwell C, Conner J, et al. Effect of oral anti-histamine on local injection site reactions with self-administered glatiramer acetate. J Neurosci Nurs 2010 Feb; 42(1): 40–6
Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987 Aug 13; 317(7): 408–14
Merck Serono Europe Limited. Rebif® (interferon beta-1a) for subcutaneous injection: EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Rebif/emea-combined-h136en.pdf [Accessed 2010 Jan 27]
Serono Inc. Rebif® (interferon beta-1a) for subcutaneous injection: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/103780s5062lbl.pdf [Accessed 2010 Jan 27]
Bayer HealthCare Pharmaceuticals Inc. Betaseron® (interferon beta-1b) for subcutaneous injection: US prescribing information [online]. Available from URL: http://www.betaseron.com/prescribing_info.jsp [Accessed 2010 Jan 27]
Bayer Schering Pharma AG. Betaferon® (interferon beta-1b) for subcutaneous injection: EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/Betaferon/emea-combined-h081en.pdf [Accessed 2010 Jan 27]
Biogen Idec Limited. Avonex® (interferon beta-1a) for intramuscular injection: EU summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/avonex/H-102-PI-en.pdf [Accessed 2010 Jan 27]
Biogen Idec Inc. Avonex® (interferon beta-1a) for intramuscular injection: US prescibing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/103628s5115lbl.pdf [Accessed 2010 Jan 27]
Association of British Neurologists. Revised (2009) guidelines for prescribing in multiple sclerosis [online]. Available from URL: http://www.theabn.org/abn/userfiles/file/ABN_MS_Guidelines_2009_Final.pdf [Accessed 2010 Feb 1]
National Institute for Clinical Excellence. Multiple sclerosis: management of multiple sclerosis in primary and secondary care [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/cg008guidance.pdf [Accessed 2010 Jan 29]
Multiple Sclerosis Therapy Consensus Group. Escalating immunotherapy of multiple sclerosis: new aspects and practical application. J Neurol 2004 Nov; 251(11): 1329–39
Compston A, Coles A. Multiple sclerosis. Lancet 2008 Oct 25; 372(9648): 1502–17
EMD Sorono Inc. Novantrone® (mitoxantrone) for injection: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/019297s030s031lbl.pdf [Accessed 2010 Feb 1]
Elan Pharma International Ltd. Tysabri® (natalizumab) 300 mg for injection: EU summary of product charactersitics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/tysabri/emea-combined-h603en.pdf [Accessed 2010 Feb 1]
Elan Pharmaceuticals Inc. Tysabri® (natalizumab) injection for intravenous use: highlights of US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/125104s0067lbl.pdf [Accessed 2010 Feb 1]
National Institute for Clinical Excellence. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/TA127Niceguidance.pdf [Accessed 2010 Feb 1]
Bertolotto A. Implications of neutralising antibodies on therapeutic efficacy. J Neurol Sci 2009 Feb 1; 277 Suppl. 1: S29–32
Marriott JJ, Miyasaki JN, Gronseth G, et al. Evidence report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010 May 4; 74(18): 1463–70
Rammohan KW, Shoemaker J. Emerging multiple sclerosis oral therapies. Neurology 2010; 74 Suppl. 1: S47–53
Carroll WM. Oral therapy for multiple sclerosis-sea change or incremental step? N Engl J Med 2010 Feb 4; 362(5): 456–8
Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362(5): 416–26
Kappos L, Radue E-W, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362(5): 387–401
Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010 Feb 4; 362(5): 402–15
Multiple Sclerosis Resource Centre. Cladribine (Mylinax) [online]. Available from URL: http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1629 [Accessed 2010 Feb 5]
Multiple Sclerosis Resource Centre. FTY720 (Fingolimod) [online]. Available from URL: http://www.msrc.co.uk/index.cfm?fuseaction=show&pageid=1309 [Accessed 2010 Feb 5]
EMD Serono. EMD Serono receives refuse to file letter from FDA on cladribine tablets new drug application [online]. Available from URL: http://www.emdserono.com/cmg.emdserono_us/en/images/20091130_Cladribine_FDA_Press%20Release%20English%20Final_US_tcm115_47509.pdf?Version= [Accessed 2010 Mar 26]
Comi G, Pulizzi A, Rovaris M, et al. Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 371: 2085–92
Sormani MP, Bonzano L, Roccatagliata L, et al. Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: a meta-analytic approach. Ann Neurol 2009; 65(3): 268–75
Petkau J, Reingold SC, Held U, et al. Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 2008 Jul; 14(6): 770–8
Daumer M, Neuhaus A, Morrissey S, et al. MRI as an outcome in multiple sclerosis clinical trials. Neurology 2009; 72: 705–11
Barkhof F, Filippi M. MRI-the perfect surrogate marker for multiple sclerosis? [letter]. Nat Rev Neurol 2009 Apr; 5(4): 182–3
Goodman AD, Rossman H, Bar-Or A, et al. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology 2009 Mar 3; 72(9): 806–12
Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006 Jun 13; 66(11): 1696–702
Thrower BW. Clinically isolated syndromes: predicting and delaying multiple sclerosis. Neurology 2007 12 Jun; 68 Suppl. 4: S12–5
Coyle PK. Early treatment of multiple sclerosis to prevent neurologic damage. Neurology 2008 Dec 9; 71 Suppl. 3: S3–7